MeiraGTx Holdings (STU:328) Other Current Payables: €0.00 Mil (As of Mar. 2026)


STU:328 MeiraGTx Holdings PLC STU:328
56 GF Score
Price €12.10
GF Value €20.56
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MeiraGTx Holdings Other Current Payables?

MeiraGTx Holdings STU:328 56 Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:328 with a GF Score™ of 56/100 and a GF Value™ of €20.56 (Possible Value Trap). The stock has 5 warning signs investors should review.

MeiraGTx Holdings's Other Current Payables for the quarter that ended in Mar. 2026 was €0.00 Mil.

MeiraGTx Holdings Other Current Payables Related Terms

MeiraGTx Holdings Other Current Payables Historical Data

* Premium members only.

The historical data trend for MeiraGTx Holdings's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeiraGTx Holdings Other Current Payables Chart

MeiraGTx Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MeiraGTx Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:328
56GF Score
MeiraGTx Holdings PLC STU:328
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeiraGTx Holdings Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.00 Mil mean?
MeiraGTx Holdings (STU:328) has a Other Current Payables of €0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on MeiraGTx Holdings and its competitors.
Is MeiraGTx Holdings' Other Current Payables too high?
MeiraGTx Holdings' current Other Current Payables is €0.00 Mil. Overall, MeiraGTx Holdings has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' Other Current Payables compare to XNCR and WVE?
MeiraGTx Holdings' Other Current Payables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on MeiraGTx Holdings and its competitors. MeiraGTx Holdings's current Other Current Payables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (STU:328) is currently considered Possible Value Trap. The stock's GF Value™ is €20.56, compared to a current price of €12.10 — trading 41.1% below its estimated fair value. The current Other Current Payables is €0.00 Mil. MeiraGTx Holdings' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For MeiraGTx Holdings (STU:328), the current Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeiraGTx Holdings (STU:328) Overvalued in 2026?

Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued. The current stock price of €12.10 is trading 41.1% below its estimated GF Value™ of €20.56. GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.

Key valuation signals for STU:328:

  • Other Current Payables: €0.00 Mil
  • GF Value™: €20.56 vs. price of €12.10 (41.1% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the STU:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MeiraGTx Holdings Business Description

Other Exchanges MGTX:USA
Address 655 Third Avenue, Suite 1115, New York, NY, USA, 10017
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
56GF Score

Get the complete analysis for STU:328

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.10
Price
€20.56
GF Value